

To the Press

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

23 April 2014

Exiqon launches LNA™ microRNA Mimics with no off-target effect

Exiqon A/S (NASDAQ OMX Copenhagen), a leading supplier of high-value gene expression analysis products, today announced the launch of highly potent miRCURY LNA™ microRNA Mimics for functional analysis.

The new miRCURY LNA™ microRNA Mimics enable sub-nanomolar potency and allow scientists to conduct high quality dose-response experiments for instance by resembling disease situations.

The highly potent miRCURY LNA™ microRNA Mimics serve to simulate the natural functions of endogenous microRNAs allowing scientists to investigate the biological function of a specific microRNA. Exiqon has developed advanced computer models to optimize the use of its proprietary LNA™ technology and ensure that only the guide-strand is active as the passenger strand is segmented into two short LNA™ strands. By applying a segmented passenger strand the passenger strand cannot be loaded into RISC which secures complete inactivity of the passenger strand thereby eliminating the main source for the well-known off-target effect of microRNA mimics.

In combination with Exiqon's proprietary miRCURY LNA™ microRNA Inhibitors and miRCURY LNA™ microRNA Target site blockers the new miRCURY LNA™ microRNA Mimics constitute a comprehensive platform for the functional analysis of microRNAs in basic research and as disease biomarkers in novel diagnostics and therapeutic applications.

"This is truly an innovative product which addresses the many requests we have received from customers" says Henrik M. Pfundheller, SVP, Sales and Marketing, and continues "We are excited to now offer customers a comprehensive high-quality product range for the functional analysis of microRNA by adding mimics to our already very popular miRCURY LNA™ microRNA Inhibitors and Target Site Blockers".

Product information on the miRCURY LNA™ microRNA Mimics can be found at www.exiqon.com/mirna-mimics

Additional information:

Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)



About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of microRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of microRNA research products for microRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on microRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com



About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of microRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of microRNA research products for microRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on microRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.

